MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 13, 2005; DOI: 10.1124/mol.105.013953


0026-895X/06/6901-317-327$20.00
Mol Pharmacol 69:317-327, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.013953v1
69/1/317    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gros, R.
Right arrow Articles by Feldman, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gros, R.
Right arrow Articles by Feldman, R. D.

The Impact of Blunted beta-Adrenergic Responsiveness on Growth Regulatory Pathways in Hypertension

Robert Gros, Qingming Ding, Jozef Chorazyczewski, Joseph Andrews, J. Geoffrey Pickering, Robert A. Hegele, and Ross D. Feldman

Departments of Medicine (R.D.F., J.G.P., R.A.H.) and Physiology and Pharmacology (R.D.F.), University of Western Ontario, London, Ontario, Canada; and Cell Signaling (R.G., Q.D., J.C., R.D.F.) and Vascular Biology (R.G., J.A., J.G.P., R.A.H., R.D.F.) Research Groups, Robarts Research Institute, London, Ontario, Canada

The effects of vasodilator hormones acting through receptors linked to adenylyl cyclase are impaired in the hypertensive state. This has been ascribed to impaired receptor-G protein coupling. However, these receptors also act via effectors not linked to adenylyl cyclase activation. These "alternate" mechanisms may be especially important in growth regulation and might be unaffected (or enhanced) with G protein-coupled receptor-G protein uncoupling. Therefore, we assessed the effects of beta-adrenergic activation on 1) regulation of phosphatidylinositol 3-kinase (PI3 kinase) and extracellular signal-regulated kinase (ERK) activation—two tyrosine kinase-dependent enzymes linked to cell growth—and 2) microarray analysis in vascular smooth muscle cells from spontaneously hypertensive rats (SHR). Isoproterenol-stimulated phosphorylation of ERK1/2 was impaired in SHR. The effect of forskolin was unaltered. In contrast, both vasopressin and angiotensin 2-mediated stimulation of ERK activation was enhanced in SHR. In addition, beta-adrenergic-mediated inhibition of PI3 kinase activity was attenuated in SHR (whereas the effect of forskolin remained intact). In microarray studies, the effect of isoproterenol to regulate transcription was significantly impaired in SHR (as was the effect of forskolin). Together, these data support the hypothesis that the blunted vasodilator effects of hormones linked to adenylyl cyclase activation are an index of a more generalized impairment in modulating growth regulatory pathways. Furthermore, this study supports the hypothesis that the blunting of beta-adrenergic responses relating to increased G protein-coupled receptor kinase 2 expression reflects a "generalized uncoupling" of beta-adrenergic-mediated responses and do not support the concept of "enhanced coupling" of "alternate" pathways of beta-adrenergic growth regulatory pathways in the hypertensive state.


Received April 21, 2005; accepted October 12, 2005

Address correspondence to: Dr. Ross D. Feldman, Robarts Research Institute, 100 Perth Dr., London, ON, Canada N6A 5K8. E-mail: feldmanr{at}lhsc.on.ca




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Gros, S. Van Uum, A. Hutchinson-Jaffe, Q. Ding, J. G. Pickering, R. A. Hegele, and R. D. Feldman
Increased Enzyme Activity and -Adrenergic Mediated Vasodilation in Subjects Expressing a Single-Nucleotide Variant of Human Adenylyl Cyclase 6
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2657 - 2663.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. Gros, Q. Ding, J. Chorazyczewski, J. G. Pickering, L. E. Limbird, and R. D. Feldman
Adenylyl Cyclase Isoform-Selective Regulation of Vascular Smooth Muscle Proliferation and Cytoskeletal Reorganization
Circ. Res., October 13, 2006; 99(8): 845 - 852.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics